RT Journal Article
SR Electronic
T1 KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.16.20190694
DO 10.1101/2020.09.16.20190694
A1 Takaharu Ichimura
A1 Yutaro Mori
A1 Philipp Aschauer
A1 Krishna M. Padmanabha Das
A1 Robert F. Padera, Jr.
A1 Astrid Weins
A1 Mahmoud L. Nasr
A1 Joseph V. Bonventre
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.09.16.20190694.abstract
AB SARS-CoV-2 precipitates respiratory distress by infection of airway epithelial cells and is often accompanied by acute kidney injury. We report that Kidney Injury Molecule-1/T cell immunoglobulin mucin domain 1 (KIM-1/TIM-1) is expressed in lung and kidney epithelial cells in COVID-19 patients and is a receptor for SARS-CoV-2. Human and mouse lung and kidney epithelial cells express KIM-1 and endocytose nanoparticles displaying the SARS-CoV-2 spike protein (virosomes). Uptake was inhibited both by anti-KIM-1 antibodies and by TW-37, our newly discovered inhibitor of KIM-1 -mediated endocytosis. Enhanced KIM-1 expression by human kidney tubuloids increased uptake of virosomes. KIM-1 positive cells express less angiotensin-converting enzyme 2 (ACE2), the well-known receptor for SARS-CoV-2. Using microscale thermophoresis, the EC50 for KIM-1-SARS-CoV-2 spike protein, and receptor binding domain (RBD) interactions, were 19 and 10 nM respectively. Thus KIM-1 is an alternative receptor to ACE2 for SARS-CoV-2. KIM-1 targeted therapeutics may prevent and/or treat COVID-19.Competing Interest StatementJ.V.B. and T.I. are co-inventors on KIM-1 patents assigned to Partners Healthcare. J.V.B. is a consultant to Cadent, Praxis and Seattle Genetics, Aldeyra, Angion and owns equity in Goldfinch, Innoviva, MediBeacon, DxNow, Verinano, Sensor Kinesis and Sentien.Funding StatementThis work was supported by grants from the National Institute of Health/NCATS/NIDDK UH3TR002155 (J.V.B.); NIDDK 2R01DK072381 (J.V.B.), R37DK039773 (J.V.B.) and Postdoctoral Fellowship from Uehara Memorial Foundation (to Y.M.), and Overseas Research Fellowships from Japan Society for the Promotion of Science (to Y.M.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Institutional Review Board of the Ethics Committee of Partners HealthcareAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the relevant data are available from the corresponding author upon reasonable request.